Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Dr. Judith Balmaña, Dr. Rebecca Dent, Prof. Simon Boulton, Prof. Sibylle Loibl, Prof. Eric Pujade-Lauraine, Prof. Charlie Gourley, Dr. Violeta Serra, Prof. Jonathan A. Ledermann
Published in the Journal of Clinical Oncology, a review paper authored by a multidisciplinary group of international experts in DNA Damage Response (DDR) and PARP inhibition
Now Published |
10 min
|
Sep 2021
I agree that this educational programme:
Other programmes of interest
Other programmes developed by Dr. Judith Balmaña
Dr. Judith Balmaña
Medical Oncologist
Vall d'Hebron University Hospital
Spain
Other programmes developed by Dr. Rebecca Dent
Dr. Rebecca Dent
Medical Oncologist
National Cancer Center Singapore
Singapore
Other programmes developed by Prof. Simon Boulton
Prof. Simon Boulton
Senior Scientist
Francis Crick Institute
United Kingdom (UK)
Other programmes developed by Prof. Eric Pujade-Lauraine
Prof. Eric Pujade-Lauraine
Gynaecologic Oncologist
Hôpital Hôtel-Dieu
France
Other programmes developed by Prof. Charlie Gourley
Prof. Charlie Gourley
Medical Oncologist
CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Re...
United Kingdom (UK)
Other programmes developed by Dr. Violeta Serra
Dr. Violeta Serra
Senior Scientist
Vall d'Hebron Institute of Oncology
Spain
Other programmes developed by Prof. Jonathan A. Ledermann
Prof. Jonathan A. Ledermann
Medical Oncologist
UCL Cancer Institute
United Kingdom (UK)